63
zeyinde düşme olmuş, bu düşmenin özellikle HBeAg kaybı olanlarda daha
belirgin olduğu görülmüştür (15).
Kaynaklar
1.
A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B
Virus Infection in the United States: Recommendations of the Advisory Committee
on Immunization Practices. Part I: Immunization of Infants, Children, and Adolescents.
MMWR 2005;54(No. RR-16):1-23.
2.
Altındiş M, Yoldaş Ö. Viral hepatitlerin tanısında serolojik ve moleküler testler. In:
Tabak F, Tosun S (eds). Viral Hepatit 2013. 1. Baskı. İstanbul: İstanbul Tıp Kitabevi,
2013:161-80.
3.
Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of
opportunistic infections in HIV-infected adults and adolescents: recommendations
from CDC, the National Institutes of Health, and the HIV Medicine Association of the
Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1-207.
4.
Lada O, Benhamou Y, Poynard T, Thibault V. Coexistence of hepatitis B surface
antigen (HBsAg) and anti-HBs antibodies in chronic hepatitis B virus carriers:
influence of “a” determinant variants. J Virol 2006;80:2968-75.
5.
Zhang JM, Xu Y, Wang XY, et al. Coexistence of hepatitis b surface antigen (HBsAg)
and heterologous subtype-specific antibodies to HBsAg among patients with
chronic hepatitis B virus. Clin Infect Dis 2007;44:1161-9.
6.
Gerlich WH. The Enigma of Concurrent Hepatitis B Surface Antigen (HBsAg) and
Antibodies to HbsAg. Clin Infect Dis 2007;44:9: 1170-2.
7.
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection.
J Hepatology 2012;57:167–185.
8.
Chevaliez S, Bouvier-Alias M, Laperche S, Pawlotsky JM. Performance of the
Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA
quantification. J Clin Microbiol 2008;46:1716–23.
9.
Cardoso AC, Carvalho-Filho RJ, Stern C, Dipumpo A, Giuily N, Ripault MP, et al.
Direct comparison of diagnostic performance of transient elastography in patients
with chronic hepatitis B and chronic hepatitis C. Liver Int 2012;32:612–21.
10.
Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK.
Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-
analysis of diagnostic accuracy. J Hepatol 2011;54:650–9.
11.
Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, et al. Hepatitis B
Virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a
in HBeAg-negative chronic hepatitis B. Hepatology. 2009;49:1141–50.
12.
Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, et
al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus
(HBV)-infection: a European perspective. J Hepatol. 2010;52:514–22.
13.
Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year
efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Gastroenterology. 2011;140:132–43.
14.
Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. HBsAg
kinetics in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil
fumarate (TDF) for up to 4 years. J Hepatol. 2011;54:740A.
15.
Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, Hansen
BE, et al. Kinetics of hepatitis B surface antigen differ between treatment with
peginterferon and entecavir. J Hepatol. 2011;54:449–54.
Hepatit B Enfeksiyonunda Tanı
